Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:N-sulfonylcarboxamide
go back to main search page
Accession:CHEBI:90852 term browser browse the term
Definition:A mixed diacylamine resulting from the formal condensation of the nitrogen of a carboxamide with a sulphonic acid.
Synonyms:related_synonym: Formula=CNO3SR3;   N-acylsulfonamide;   N-acylsulfonamides;   N-carboacylsulfonamide;   N-carboacylsulfonamides;   N-sulfonylcarboxamides;   SMILES=C(=O)(N(S(*)(=O)=O)*)*


show annotations for term's descendants           Sort by:
ABT-737 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]] CTD PMID:32802178 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bag3 BAG cochaperone 3 decreases response to substance
multiple interactions		 ISO BAG3 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]		 CTD PMID:23341456 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects folding
multiple interactions		 ISO ABT-737 affects the folding of BAX protein
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [ABT-737 co-treated with hydroquinone] results in increased expression of BAX protein; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]		 CTD PMID:17097560 PMID:17200714 PMID:21880625 PMID:28843007 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance		 ISO ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Vorinostat]
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased phosphorylation of BCL2 protein] which results in increased susceptibility to ABT-737; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [ABT-737 results in decreased activity of BCL2 protein] which results in increased susceptibility to fosbretabulin; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]
BCL2 protein modified form results in decreased susceptibility to ABT-737		 CTD PMID:17097560 PMID:17200714 PMID:19060243 PMID:20104024 PMID:24321340 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
increases expression		 ISO ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Vorinostat]
ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]
ABT-737 results in increased expression of BCL2L1 protein alternative form		 CTD PMID:18628207 PMID:19060243 PMID:21256112 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases response to substance		 ISO [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]
BCL2L11 protein results in increased susceptibility to ABT-737		 CTD PMID:17097560 PMID:17200714 PMID:20038611 PMID:23341456 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Becn1 beclin 1 multiple interactions ISO ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]] CTD PMID:18628207 PMID:32061152 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [ABT-737 co-treated with Celecoxib] results in increased cleavage of BID protein CTD PMID:20104024 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463 		JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity		 ISO ABT-737 results in increased cleavage of CASP3 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP3 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP3 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]
ABT-737 results in increased activity of CASP3 protein		 CTD PMID:19010845 PMID:19773376 PMID:20038611 PMID:20104024 PMID:23353698 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 increases activity ISO ABT-737 results in increased activity of CASP7 protein CTD PMID:20038611 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp8 caspase 8 increases cleavage
multiple interactions		 ISO ABT-737 results in increased cleavage of CASP8 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP8 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]		 CTD PMID:20104024 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 increases activity
increases cleavage
multiple interactions		 ISO ABT-737 results in increased activity of CASP9 protein
ABT-737 results in increased cleavage of CASP9 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP9 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP9 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]		 CTD PMID:20104024 PMID:23353698 PMID:30461186 PMID:33662508 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G H2ax H2A.X variant histone multiple interactions ISO [ABT-737 co-treated with hydroquinone] results in increased expression of H2AX protein CTD PMID:28843007 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Krt18 keratin 18 increases cleavage ISO ABT-737 results in increased cleavage of KRT18 protein CTD PMID:19010845 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases response to substance
multiple interactions		 ISO MCL1 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; [Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]		 CTD PMID:17097560 PMID:17688235 PMID:21880625 PMID:23341456 PMID:32802178 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions
decreases expression		 ISO [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
ABT-737 results in decreased expression of MKI67 protein		 CTD PMID:19773376 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Nanog Nanog homeobox decreases expression ISO ABT-737 results in decreased expression of NANOG protein CTD PMID:23918355 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein; [ABT-737 co-treated with hydroquinone] results in increased cleavage of PARP1 protein; ABT-737 inhibits the reaction [hydroquinone affects the localization of PARP1 protein]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:28843007 PMID:32802178 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases response to substance ISO PMAIP1 protein results in increased susceptibility to ABT-737 CTD PMID:17688235 NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429 		JBrowse link
G Rassf1 Ras association domain family member 1 multiple interactions ISO ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Cisplatin]; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] CTD PMID:21880625 NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Celecoxib co-treated with ABT-737] results in decreased expression of SQSTM1 protein; ABT-737 promotes the reaction [Silicon Dioxide results in decreased expression of SQSTM1 protein] CTD PMID:20104024 PMID:32061152 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [ABT-737 co-treated with hydroquinone] results in increased expression of TRP53 protein CTD PMID:28843007 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Usp7 ubiquitin specific peptidase 7 multiple interactions ISO USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:32802178 NCBI chr10:6,880,684...6,925,355
Ensembl chr10:6,828,795...6,925,355 		JBrowse link
fomesafen term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcd3 ATP binding cassette subfamily D member 3 increases expression ISO fomesafen results in increased expression of ABCD3 mRNA CTD PMID:22539621 NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020 		JBrowse link
G Acot1 acyl-CoA thioesterase 1 increases expression ISO fomesafen results in increased expression of ACOT1 mRNA CTD PMID:22539621 NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163 		JBrowse link
G Acox1 acyl-CoA oxidase 1 increases expression ISO fomesafen results in increased expression of ACOX1 mRNA CTD PMID:22539621 NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232 		JBrowse link
G Alas1 5'-aminolevulinate synthase 1 increases expression ISO fomesafen results in increased expression of ALAS1 mRNA CTD PMID:12758057 NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917 		JBrowse link
G Urod uroporphyrinogen decarboxylase decreases activity ISO fomesafen results in decreased activity of UROD protein CTD PMID:12758057 NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808 		JBrowse link
navitoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO [navitoclax co-treated with Vorinostat] affects the activity of BAK1 protein CTD PMID:21652541 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [navitoclax co-treated with Vorinostat] affects the activity of BAX protein CTD PMID:21652541 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions		 ISO navitoclax results in decreased expression of BIRC5 protein
[MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]		 CTD PMID:28947240 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions		 ISO navitoclax results in increased cleavage of CASP3 protein
[navitoclax co-treated with GSK923295] results in increased activity of CASP3 protein; [navitoclax co-treated with Vorinostat] results in increased activity of CASP3 protein		 CTD PMID:21562047 PMID:21652541 PMID:38258067 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 increases cleavage ISO navitoclax results in increased cleavage of CASP9 protein CTD PMID:21562047 PMID:28947240 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Gsn gelsolin increases cleavage ISO navitoclax results in increased cleavage of GSN protein CTD PMID:21562047 NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402 		JBrowse link
G Mtor mechanistic target of rapamycin kinase affects response to substance
multiple interactions		 ISO MTOR protein affects the susceptibility to navitoclax
[MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein		 CTD PMID:28947240 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO [MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein; rucaparib promotes the reaction [navitoclax results in increased cleavage of PARP1 protein] CTD PMID:28947240 PMID:32927276 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
parecoxib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdh1 cadherin 1 increases expression ISO parecoxib results in increased expression of CDH1 protein CTD PMID:35917206 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cnr1 cannabinoid receptor 1 increases response to substance ISO CNR1 protein results in increased susceptibility to parecoxib CTD PMID:23371449 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099 		JBrowse link
G Ctnnb1 catenin beta 1 decreases expression ISO parecoxib results in decreased expression of CTNNB1 protein CTD PMID:35917206 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression
increases expression		 ISO parecoxib results in decreased expression of GSK3B protein modified form
parecoxib results in increased expression of GSK3B protein		 CTD PMID:35917206 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Macc1 MET transcriptional regulator MACC1 decreases expression ISO parecoxib results in decreased expression of MACC1 protein CTD PMID:35917206 NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:140,352,755...140,430,255 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO parecoxib results in decreased phosphorylation of MAPK1 protein CTD PMID:35917206 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO parecoxib results in decreased phosphorylation of MAPK3 protein CTD PMID:35917206 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation ISO parecoxib results in increased phosphorylation of MAPK8 protein CTD PMID:35917206 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation ISO parecoxib results in increased phosphorylation of MAPK9 protein CTD PMID:35917206 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases expression ISO parecoxib results in decreased expression of MET protein CTD PMID:35917206 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Vim vimentin decreases expression ISO parecoxib results in decreased expression of VIM protein CTD PMID:35917206 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187 		JBrowse link
saccharin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Afp alpha-fetoprotein increases expression ISO Saccharin results in increased expression of AFP mRNA CTD PMID:26272751 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480 		JBrowse link
G Car13 carbonic anhydrase 13 increases expression ISO Saccharin results in increased expression of CAR13 mRNA CTD PMID:19000923 NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525 		JBrowse link
G Car3 carbonic anhydrase 3 multiple interactions ISO Saccharin binds to and results in decreased activity of CA3 protein CTD PMID:17826101 NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 increases expression ISO Saccharin results in increased expression of CDK1 mRNA CTD PMID:26272751 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cer1 cerberus 1, DAN family BMP antagonist increases expression ISO Saccharin results in increased expression of CER1 mRNA CTD PMID:26272751 NCBI chr 5:97,306,427...97,309,783
Ensembl chr 5:97,306,431...97,309,783 		JBrowse link
G Chek1 checkpoint kinase 1 increases expression ISO Saccharin results in increased expression of CHEK1 mRNA CTD PMID:19000923 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009 		JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression ISO Saccharin results in increased expression of FOSL1 mRNA CTD PMID:19000923 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930 		JBrowse link
G Gnat3 G protein subunit alpha transducin 3 affects response to substance ISO GNAT3 protein affects the susceptibility to Saccharin CTD PMID:16740645 NCBI chr 4:17,162,500...17,212,283
Ensembl chr 4:17,162,490...17,212,283 		JBrowse link
G Hdac7 histone deacetylase 7 decreases expression ISO Saccharin results in decreased expression of HDAC7 mRNA CTD PMID:26272751 NCBI chr 7:128,923,918...128,961,926
Ensembl chr 7:128,923,920...128,962,072 		JBrowse link
G Hells helicase, lymphoid specific increases expression ISO Saccharin results in increased expression of HELLS mRNA CTD PMID:19000923 NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844 		JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 increases expression ISO Saccharin results in increased expression of IL1RL1 mRNA CTD PMID:19000923 NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO Saccharin results in increased expression of JUN mRNA CTD PMID:19000923 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit increases expression ISO Saccharin results in increased expression of JUNB mRNA CTD PMID:19000923 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035 		JBrowse link
G Kdr kinase insert domain receptor increases expression ISO Saccharin results in increased expression of KDR mRNA CTD PMID:26272751 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 increases expression ISO Saccharin results in increased expression of MCM3 mRNA CTD PMID:19000923 NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314 		JBrowse link
G Mesp1 mesoderm posterior bHLH transcription factor 1 decreases expression ISO Saccharin results in decreased expression of MESP1 mRNA CTD PMID:26272751 NCBI chr 1:133,738,357...133,739,875
Ensembl chr 1:133,738,357...133,739,875 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO Saccharin results in increased expression of MYC mRNA CTD PMID:26272751 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myo1e myosin IE increases expression ISO Saccharin results in increased expression of MYO1E mRNA CTD PMID:26272751 NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169 		JBrowse link
G Nes nestin increases expression ISO Saccharin results in increased expression of NES mRNA CTD PMID:26272751 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777 		JBrowse link
G Nos2 nitric oxide synthase 2 increases expression ISO Saccharin results in increased expression of NOS2 mRNA CTD PMID:28472674 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nup54 nucleoporin 54 increases expression ISO Saccharin results in increased expression of NUP54 mRNA CTD PMID:19000923 NCBI chr14:15,617,630...15,636,029
Ensembl chr14:15,617,679...15,636,028 		JBrowse link
G Orm1 orosomucoid 1 increases expression ISO Saccharin results in increased expression of ORM1 mRNA CTD PMID:19000923 NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154 		JBrowse link
G Phex phosphate regulating endopeptidase X-linked increases expression ISO Saccharin results in increased expression of PHEX mRNA CTD PMID:19000923 NCBI chr  X:37,607,553...37,856,183
Ensembl chr  X:37,610,760...37,854,469 		JBrowse link
G Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 increases expression ISO Saccharin results in increased expression of PIK3R5 mRNA CTD PMID:19000923 NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374 		JBrowse link
G Pnpla6 patatin-like phospholipase domain containing 6 decreases expression ISO Saccharin results in decreased expression of PNPLA6 mRNA CTD PMID:26272751 NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Saccharin co-treated with Glucose] binds to PPARA protein; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] CTD PMID:18812576 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Rad21 RAD21 cohesin complex component increases expression ISO Saccharin results in increased expression of RAD21 mRNA CTD PMID:19000923 NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817 		JBrowse link
G Rif1 replication timing regulatory factor 1 increases expression ISO Saccharin results in increased expression of RIF1 mRNA CTD PMID:19000923 NCBI chr 3:36,554,689...36,607,961
Ensembl chr 3:36,554,697...36,603,617 		JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression ISO Saccharin results in increased expression of SCARB1 mRNA CTD PMID:19000923 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647 		JBrowse link
G Shh sonic hedgehog signaling molecule decreases expression ISO Saccharin results in decreased expression of SHH mRNA CTD PMID:26272751 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170 		JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Saccharin results in increased expression of SLC2A1 mRNA CTD PMID:19000923 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416 		JBrowse link
G Stmn1 stathmin 1 increases expression ISO Saccharin results in increased expression of STMN1 mRNA CTD PMID:19000923 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154 		JBrowse link
G Tas1r3 taste 1 receptor member 3 affects response to substance
multiple interactions		 ISO TAS1R3 protein affects the susceptibility to Saccharin
TRPV1 protein affects the reaction [TAS1R3 protein affects the susceptibility to Saccharin]		 CTD PMID:18804451 NCBI chr 5:166,468,703...166,472,759
Ensembl chr 5:166,469,589...166,472,742 		JBrowse link
G Tas2r136 taste receptor, type 2, member 136 increases activity ISO Saccharin results in increased activity of TAS2R31 protein CTD PMID:21629661 NCBI chr 4:166,098,848...166,099,840
Ensembl chr 4:166,098,848...166,099,840 		JBrowse link
G Tfrc transferrin receptor increases expression ISO Saccharin results in increased expression of TFRC mRNA CTD PMID:19000923 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257 		JBrowse link
G Tnf tumor necrosis factor increases expression ISO Saccharin results in increased expression of TNF mRNA CTD PMID:28472674 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions
increases activity		 ISO TRPV1 protein affects the reaction [TAS1R3 protein affects the susceptibility to Saccharin]
Saccharin results in increased activity of TRPV1 protein		 CTD PMID:17567713 PMID:18804451 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513 		JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Saccharin results in increased expression of VEGFA mRNA CTD PMID:19000923 PMID:26272751 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Wnt3 Wnt family member 3 increases expression ISO Saccharin results in increased expression of WNT3 mRNA CTD PMID:26272751 NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099 		JBrowse link
sulfacetamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hmbs hydroxymethylbilane synthase decreases activity EXP Sulfacetamide decreases activity of purified Hmbs protein RGD PMID:6893114 RGD:26923963 NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957 		JBrowse link
venetoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO [venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein]] which results in decreased export of Daunorubicin; venetoclax inhibits the reaction [Daunorubicin results in increased expression of ABCB1 protein] CTD PMID:34963561 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 affects binding ISO venetoclax binds to ABCG2 protein CTD PMID:33954893 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 affects folding ISO venetoclax affects the folding of BAK1 protein CTD PMID:30647404 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects folding ISO venetoclax affects the folding of BAX protein CTD PMID:30647404 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 affects response to substance
multiple interactions		 ISO BBC3 protein affects the susceptibility to venetoclax
2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [BBC3 protein affects the susceptibility to venetoclax]; BBC3 protein affects the susceptibility to [venetoclax co-treated with pitavastatin]		 CTD PMID:37956312 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases activity
decreases expression
multiple interactions		 ISO venetoclax results in decreased activity of BCL2 protein
venetoclax results in decreased expression of BCL2 protein
[9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of BCL2 protein; [mivebresib co-treated with venetoclax] results in decreased expression of BCL2 protein		 CTD PMID:26214592 PMID:30647404 PMID:37754227 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression
multiple interactions		 ISO venetoclax results in decreased expression of BCL2L1 protein
[mivebresib co-treated with venetoclax] results in decreased expression of BCL2L1 protein		 CTD PMID:30647404 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [sepantronium co-treated with venetoclax] results in decreased expression of BIRC5 protein CTD PMID:31837377 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Btrc beta-transducin repeat containing E3 ubiquitin protein ligase multiple interactions ISO 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA; [WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Dactinomycin promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA] CTD PMID:35561756 NCBI chr 1:244,210,299...244,380,126
Ensembl chr 1:244,210,314...244,376,721 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage		 ISO [venetoclax co-treated with sepantronium] results in increased cleavage of CASP3 protein; venetoclax inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of CASP3 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of CASP3 protein] CTD PMID:31837377 PMID:34303041 PMID:34861246 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO [venetoclax co-treated with sepantronium] results in increased cleavage of CASP9 protein CTD PMID:31837377 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCP1 protein] CTD PMID:35561756 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions ISO [mivebresib co-treated with venetoclax] results in decreased expression of CDK6 protein CTD PMID:30647404 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 decreases expression
multiple interactions		 ISO venetoclax results in decreased expression of FLT3 protein
9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- promotes the reaction [venetoclax results in decreased expression of FLT3 protein]; [9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- co-treated with venetoclax] results in decreased expression of FLT3 protein		 CTD PMID:37754227 NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK1 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK1 protein CTD PMID:35561756 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased phosphorylation of MAPK3 protein; [venetoclax co-treated with WEHI-539] results in decreased phosphorylation of MAPK3 protein CTD PMID:35561756 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression
decreases expression
multiple interactions		 ISO venetoclax results in increased expression of MCL1 protein
venetoclax results in decreased expression of MCL1 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; [mivebresib co-treated with venetoclax] results in decreased expression of MCL1 protein; [sepantronium co-treated with venetoclax] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein; [WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]		 CTD PMID:30647404 PMID:31837377 PMID:35561756 PMID:37754227 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [mivebresib co-treated with venetoclax] results in decreased expression of MYC protein CTD PMID:30647404 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions ISO [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in increased expression of NOX4 protein; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 mRNA; [venetoclax co-treated with WEHI-539] results in increased expression of NOX4 protein CTD PMID:35561756 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO [mivebresib co-treated with venetoclax] results in increased cleavage of PARP1 protein; [venetoclax co-treated with sepantronium] results in increased cleavage of PARP1 protein; venetoclax promotes the reaction [ZCL-082 results in increased cleavage of PARP1 protein]; ZCL-082 promotes the reaction [venetoclax results in increased cleavage of PARP1 protein] CTD PMID:30647404 PMID:31837377 PMID:34861246 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
affects response to substance
increases expression		 ISO 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA; [WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 mRNA]; mithramycin A inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; PMAIP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein]
PMAIP1 protein affects the susceptibility to venetoclax
venetoclax results in increased expression of PMAIP1 protein		 CTD PMID:30647404 PMID:35561756 PMID:37956312 NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of SP1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; [WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein; [WEHI-539 co-treated with venetoclax] results in increased expression of and results in increased stability of SP1 protein; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of SP1 protein]; BTRC protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in increased expression of PMAIP1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]; SP1 protein affects the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein] CTD PMID:35561756 NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]; [venetoclax co-treated with WEHI-539 co-treated with hydroquinone] results in decreased expression of SQSTM1 protein; [venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein] CTD PMID:35561756 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
zafirlukast term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO zafirlukast results in decreased activity of ABCB11 protein CTD PMID:23956101 PMID:28437613 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO zafirlukast results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO zafirlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] CTD PMID:15180633 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Bmp6 bone morphogenetic protein 6 increases expression ISO zafirlukast results in increased expression of BMP6 mRNA CTD PMID:32816093 NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365 		JBrowse link
G Cat catalase increases expression EXP zafirlukast results in increased expression of CAT protein CTD PMID:12962976 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO zafirlukast results in decreased activity of CYP1A1 protein CTD PMID:33814510 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO zafirlukast inhibits the reaction [CYP1A2 protein results in increased metabolism of Theophylline] CTD PMID:9701106 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO zafirlukast results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 multiple interactions
decreases activity		 ISO zafirlukast inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]
zafirlukast results in decreased activity of CYP2C19 protein		 CTD PMID:15370959 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO zafirlukast results in decreased activity of CYP2C8 protein CTD PMID:15601807
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity
multiple interactions
increases metabolic processing		 ISO zafirlukast metabolite results in decreased activity of CYP3A4 protein; zafirlukast results in decreased activity of CYP3A4 protein
zafirlukast inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]
CYP3A4 protein results in increased metabolism of zafirlukast		 CTD PMID:15370959 PMID:16167835 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cysltr1 cysteinyl leukotriene receptor 1 multiple interactions
affects binding		 ISO [zafirlukast binds to and results in decreased activity of CYSLTR1 protein] which affects the abundance of Calcium; alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol inhibits the reaction [zafirlukast binds to and results in decreased activity of CYSLTR1 protein]; zafirlukast binds to and results in decreased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]]; zafirlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; zafirlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein]
zafirlukast binds to and results in decreased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
zafirlukast binds to CYSLTR1 protein		 CTD PMID:1554195 PMID:8014876 PMID:8384568 PMID:8389103 PMID:8389105 More... NCBI chr  X:71,661,421...71,690,012
Ensembl chr  X:71,663,821...71,690,121 		JBrowse link
G Cysltr2 cysteinyl leukotriene receptor 2 multiple interactions ISO zafirlukast binds to and results in decreased activity of CYSLTR2 protein; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein] CTD PMID:10851239 NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136 		JBrowse link
G Edn1 endothelin 1 multiple interactions
decreases expression		 ISO zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 mRNA]; zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 protein]
zafirlukast results in decreased expression of EDN1 protein		 CTD PMID:11372388 PMID:12781059 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Ereg epiregulin increases expression ISO zafirlukast results in increased expression of EREG mRNA CTD PMID:32816093 NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [zafirlukast co-treated with Prednisone co-treated with Budesonide] inhibits the reaction [Antigens results in increased secretion of IFNG protein] CTD PMID:16160912 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il1b interleukin 1 beta decreases expression ISO zafirlukast results in decreased expression of IL1B mRNA CTD PMID:32816093 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il24 interleukin 24 increases expression ISO zafirlukast results in increased expression of IL24 mRNA CTD PMID:32816093 NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein] CTD PMID:18704935 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase increases expression ISO zafirlukast results in increased expression of MET mRNA CTD PMID:32816093 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein] CTD PMID:31816286 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein] CTD PMID:31816286 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mpo myeloperoxidase decreases activity
decreases expression		 EXP zafirlukast results in decreased activity of MPO protein
zafirlukast results in decreased expression of MPO protein		 CTD PMID:11438310 PMID:12962976 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819 		JBrowse link
G Ocln occludin multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of OCLN mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of OCLN protein] CTD PMID:31816286 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150 		JBrowse link
G Pid1 phosphotyrosine interaction domain containing 1 increases expression ISO zafirlukast results in increased expression of PID1 mRNA CTD PMID:32816093 NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO zafirlukast results in increased expression of PTGS2 mRNA CTD PMID:32816093 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rnase3 ribonuclease A family member 3 decreases expression ISO zafirlukast results in decreased expression of RNASE3 protein CTD PMID:15612964 NCBI chr15:24,511,894...24,512,764
Ensembl chr15:24,511,891...24,512,790 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO zafirlukast inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Slc47a1 solute carrier family 47 member 1 multiple interactions ISO zafirlukast inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637 		JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO zafirlukast inhibits the reaction [SLC47A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression ISO zafirlukast results in decreased expression of SLC7A11 mRNA CTD PMID:32816093 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536 		JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO zafirlukast results in increased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TJP1 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TJP1 protein] CTD PMID:31816286 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein] CTD PMID:18704935 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfaip6 TNF alpha induced protein 6 decreases expression ISO zafirlukast results in decreased expression of TNFAIP6 mRNA CTD PMID:32816093 NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19901
    chemical entity 19899
      atom 19899
        nonmetal atom 19822
          nitrogen atom 19006
            nitrogen molecular entity 19006
              amide 17801
                secondary amide 6461
                  imide 6460
                    mixed diacylamine 142
                      N-sulfonylcarboxamide 129
                        (Z)-11-methyl-N-(methylsulfonyl)dodec-2-enamide 0
                        ABT-737 28
                        HMN-214 0
                        L-798106 0
                        N-[(1S)-1-(1H-benzimidazol-2-yl)-2-\{4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}ethyl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide 0
                        N-\{(1S)-2-\{4-[(5R)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl\}-2,2,2-trifluoroacetamide 0
                        N-\{[4-(1,1-dioxido-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)phenyl]acetyl\}-L-phenylalanyl-4-(1,1-dioxido-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)-L-phenylalaninamide 0
                        N-acetyl-L-phenylalanyl-4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]-L-phenylalaninamide 0
                        N-benzoyl-L-phenylalanyl-4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]-L-phenylalaninamide 0
                        \{4-[(carboxymethoxy)carbonyl]-3,3-dioxido-1-oxonaphtho[1,2-d]-1,2-thiazol-2(1H)-yl\}acetic acid 0
                        cyprosulfamide 0
                        fluazaindolizine 0
                        fomesafen 5
                        grazoprevir + 0
                        metcamifen 0
                        methyl 2-\{[5-(\{3-chloro-4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]-N-(phenylsulfonyl)-L-phenylalanyl\}amino)pentyl]oxy\}-6-hydroxybenzoate 0
                        navitoclax 8
                        parecoxib 11
                        paritaprevir + 0
                        saccharin + 39
                        selexipag 0
                        sulfacetamide 1
                        tasisulam 0
                        vaniprevir 0
                        venetoclax 23
                        zafirlukast 35
Path 2
Term Annotations click to browse term
  CHEBI ontology 19901
    subatomic particle 19899
      composite particle 19899
        hadron 19899
          baryon 19899
            nucleon 19899
              atomic nucleus 19899
                atom 19899
                  main group element atom 19838
                    p-block element atom 19838
                      pnictogen 19102
                        nitrogen atom 19006
                          nitrogen molecular entity 19006
                            amide 17801
                              secondary amide 6461
                                imide 6460
                                  mixed diacylamine 142
                                    N-sulfonylcarboxamide 129
                                      (Z)-11-methyl-N-(methylsulfonyl)dodec-2-enamide 0
                                      ABT-737 28
                                      HMN-214 0
                                      L-798106 0
                                      N-[(1S)-1-(1H-benzimidazol-2-yl)-2-\{4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}ethyl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide 0
                                      N-\{(1S)-2-\{4-[(5R)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]phenyl\}-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl\}-2,2,2-trifluoroacetamide 0
                                      N-\{[4-(1,1-dioxido-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)phenyl]acetyl\}-L-phenylalanyl-4-(1,1-dioxido-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)-L-phenylalaninamide 0
                                      N-acetyl-L-phenylalanyl-4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]-L-phenylalaninamide 0
                                      N-benzoyl-L-phenylalanyl-4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]-L-phenylalaninamide 0
                                      \{4-[(carboxymethoxy)carbonyl]-3,3-dioxido-1-oxonaphtho[1,2-d]-1,2-thiazol-2(1H)-yl\}acetic acid 0
                                      cyprosulfamide 0
                                      fluazaindolizine 0
                                      fomesafen 5
                                      grazoprevir + 0
                                      metcamifen 0
                                      methyl 2-\{[5-(\{3-chloro-4-[(5S)-1,1-dioxido-3-oxo-1,2-thiazolidin-5-yl]-N-(phenylsulfonyl)-L-phenylalanyl\}amino)pentyl]oxy\}-6-hydroxybenzoate 0
                                      navitoclax 8
                                      parecoxib 11
                                      paritaprevir + 0
                                      saccharin + 39
                                      selexipag 0
                                      sulfacetamide 1
                                      tasisulam 0
                                      vaniprevir 0
                                      venetoclax 23
                                      zafirlukast 35
paths to the root